These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 3897170)

  • 1. Comparative in-vitro activity of Sch 34343, imipenem, cefpirome and cefotaxime.
    Bauernfeind A
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():155-64. PubMed ID: 3897170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of CGP 31608, a new penem.
    Wise R; Andrews JM; Piddock LJ
    Antimicrob Agents Chemother; 1987 Feb; 31(2):267-73. PubMed ID: 3105451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial properties of imipenem with special reference to the activity against methicillin-resistant staphylococci, cefotaxime-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Vurma-Rapp U; Kayser FH; Barberis-Maino L
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():27-33. PubMed ID: 3102452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro evaluation of Sch 34343: antimicrobial activity, beta-lactamase stability and inhibition.
    Jones RN; Barry AL; Fuchs PC; Thornsberry C
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():99-109. PubMed ID: 3875606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centres.
    Reeves DS; Bywater MJ; Holt HA
    J Antimicrob Chemother; 1993 Mar; 31(3):345-62. PubMed ID: 8486569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of cefpirome against microorganisms isolated in haematology, oncology and intensive care units in Switzerland.
    Liassine N; Bille J; Breer C; Frei R; Wüst J; Auckenthaler R
    Scand J Infect Dis; 1997; 29(6):615-21. PubMed ID: 9571744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.
    Braveny I; Machka K; Elsser R
    Infection; 1982 Jan; 10(1):45-9. PubMed ID: 6279523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
    Medeiros AA; Hare R; Papa E; Adam C; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics.
    Neu HC; Chin NX; Labthavikul P
    J Antimicrob Chemother; 1985 Sep; 16(3):305-13. PubMed ID: 2997100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
    Bauernfeind A; Schweighart S; Eberlein E; Jungwirth R
    Infection; 1991; 19 Suppl 5():S264-75. PubMed ID: 1664418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of imipenem--a review.
    Braveny I
    Eur J Clin Microbiol; 1984 Oct; 3(5):456-62. PubMed ID: 6389125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sensitivity to cefotiam of 494 hospital bacterial strains. Determination of minimal inhibitory concentration and comparison with other beta-lactams].
    Reynaud A; Desnoes M; Derriennic M; Courtieu AL
    Pathol Biol (Paris); 1985 May; 33(5):313-9. PubMed ID: 3929216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of cefepime and other broad-spectrum beta-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group.
    Lewis MT; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):285-90. PubMed ID: 10668587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the in-vitro antibacterial activity of Sch 34343.
    Adam C; Naples L; Weiss W; Sabatelli F; Hare R; Loebenberg D; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():39-56. PubMed ID: 3875604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents.
    Cheng AF; Ling TK; Lam AW; Fung KS; Wise R
    J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria.
    Pusztai-Markos Z; Pranada F
    Eur J Clin Microbiol; 1982 Feb; 1(1):49-51. PubMed ID: 6293811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sch 34343: in-vitro antibacterial activity and susceptibility to beta-lactamases.
    Shannon K; King A; Phillips I
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():15-23. PubMed ID: 3897169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Activity of fourth generation cephalosporins against clinical isolates of Enterobacteriaceae].
    Tuchiluş C; Poiată A; Bădicuţ I; Teodor A; Luca V; Grigore L; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):595-8. PubMed ID: 14756068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro antibacterial activity of imipenem compared with four other beta-lactam antibiotics (ceftazidime, cefotaxime, piperacillin and azlocillin) against 828 separate clinical isolates from a Portuguese hospital.
    Santos-Ferreira MO; Vital JO
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():23-6. PubMed ID: 3469195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.